Hemostemix Inc (HEM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.839x

Based on the latest financial reports, Hemostemix Inc (HEM) has a cash flow conversion efficiency ratio of 0.839x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-2.91 Million ≈ $-2.10 Million USD) by net assets (CA$-3.46 Million ≈ $-2.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hemostemix Inc - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Hemostemix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Hemostemix Inc for a breakdown of total debt and financial obligations.

Hemostemix Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hemostemix Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Garovaglio y Zorraquin S.A.
BA:GARO
-0.041x
Inter-Delta Tbk
JK:INTD
-0.225x
Oceancash Pacific Bhd
KLSE:0049
-0.012x
Avalon Holdings Corporation
NYSE MKT:AWX
0.039x
Eurasia Fonciere Investissements Société Anonyme
PA:EFI
-0.015x
LabGenomics Co. Ltd
KQ:084650
-0.034x
Axiom Properties Ltd
AU:AXI
-0.145x
Pharmacielo Ltd
V:PCLO
0.236x

Annual Cash Flow Conversion Efficiency for Hemostemix Inc (2013–2024)

The table below shows the annual cash flow conversion efficiency of Hemostemix Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Hemostemix Inc market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CA$-7.20 Million
≈ $-5.21 Million
CA$-1.90 Million
≈ $-1.38 Million
0.264x +29.94%
2023-12-31 CA$-7.37 Million
≈ $-5.33 Million
CA$-1.50 Million
≈ $-1.08 Million
0.203x -77.46%
2022-12-31 CA$-6.77 Million
≈ $-4.90 Million
CA$-6.10 Million
≈ $-4.41 Million
0.901x +36.96%
2021-12-31 CA$-5.28 Million
≈ $-3.82 Million
CA$-3.48 Million
≈ $-2.52 Million
0.658x -87.90%
2020-12-31 CA$-1.10 Million
≈ $-794.78K
CA$-5.98 Million
≈ $-4.32 Million
5.438x +546.31%
2019-12-31 CA$-4.05 Million
≈ $-2.93 Million
CA$-3.40 Million
≈ $-2.46 Million
0.841x +115.26%
2018-12-31 CA$487.80K
≈ $352.87K
CA$-2.69 Million
≈ $-1.95 Million
-5.513x -730.03%
2017-12-31 CA$4.84 Million
≈ $3.50 Million
CA$-3.21 Million
≈ $-2.32 Million
-0.664x -185.48%
2016-12-31 CA$-3.46 Million
≈ $-2.50 Million
CA$-2.69 Million
≈ $-1.95 Million
0.777x +103.82%
2015-12-31 CA$174.08K
≈ $125.93K
CA$-3.55 Million
≈ $-2.56 Million
-20.365x -2102.29%
2014-12-31 CA$3.39 Million
≈ $2.45 Million
CA$-3.13 Million
≈ $-2.27 Million
-0.925x +52.07%
2013-12-31 CA$573.87K
≈ $415.13K
CA$-1.11 Million
≈ $-800.95K
-1.929x --

About Hemostemix Inc

V:HEM Canada Biotechnology
Market Cap
$8.18 Million
CA$11.31 Million CAD
Market Cap Rank
#27339 Global
#1183 in Canada
Share Price
CA$0.06
Change (1 day)
+0.00%
52-Week Range
CA$0.06 - CA$0.15
All Time High
CA$13.40
About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more